BR112022013601A2 - Anticorpos específicos de caderina epitelial - Google Patents
Anticorpos específicos de caderina epitelialInfo
- Publication number
- BR112022013601A2 BR112022013601A2 BR112022013601A BR112022013601A BR112022013601A2 BR 112022013601 A2 BR112022013601 A2 BR 112022013601A2 BR 112022013601 A BR112022013601 A BR 112022013601A BR 112022013601 A BR112022013601 A BR 112022013601A BR 112022013601 A2 BR112022013601 A2 BR 112022013601A2
- Authority
- BR
- Brazil
- Prior art keywords
- specific antibodies
- epithelial cadherin
- cadherin specific
- epithelial
- cadherin antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20151325 | 2020-01-10 | ||
| PCT/NL2021/050009 WO2021141492A1 (en) | 2020-01-10 | 2021-01-08 | Epithelial cadherin-specific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013601A2 true BR112022013601A2 (pt) | 2022-09-13 |
Family
ID=69159601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013601A BR112022013601A2 (pt) | 2020-01-10 | 2021-01-08 | Anticorpos específicos de caderina epitelial |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317880A1 (https=) |
| EP (1) | EP4087872A1 (https=) |
| JP (1) | JP2023509973A (https=) |
| KR (1) | KR20220131527A (https=) |
| CN (2) | CN115066439A (https=) |
| AU (1) | AU2021206586A1 (https=) |
| BR (1) | BR112022013601A2 (https=) |
| CA (1) | CA3163286A1 (https=) |
| IL (1) | IL294342A (https=) |
| MX (1) | MX2022008391A (https=) |
| WO (1) | WO2021141492A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| AU2011319777B2 (en) * | 2010-10-27 | 2016-12-08 | The Research Foundation For The State University Of New York | Compositions targeting the soluble extracellular domain of E-cadherin and related methods for cancer therapy |
| ES2931477T3 (es) * | 2010-10-29 | 2022-12-29 | Perseus Proteomics Inc | Anticuerpo anti-CDH3 que tiene alta capacidad de internalización |
| KR102276528B1 (ko) * | 2011-09-30 | 2021-07-12 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존성 결합 분자 라이브러리 |
| EP2785737A2 (en) | 2011-12-02 | 2014-10-08 | AIMM Therapeutics B.V. | Influenza a virus specific antibodies |
| US9534058B2 (en) * | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
| SG11201601424PA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
| WO2015093949A2 (en) | 2013-12-17 | 2015-06-25 | Aimm Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
| AU2016356780A1 (en) * | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
-
2021
- 2021-01-08 BR BR112022013601A patent/BR112022013601A2/pt unknown
- 2021-01-08 MX MX2022008391A patent/MX2022008391A/es unknown
- 2021-01-08 CA CA3163286A patent/CA3163286A1/en active Pending
- 2021-01-08 US US17/789,940 patent/US20240317880A1/en active Pending
- 2021-01-08 AU AU2021206586A patent/AU2021206586A1/en active Pending
- 2021-01-08 KR KR1020227027102A patent/KR20220131527A/ko active Pending
- 2021-01-08 WO PCT/NL2021/050009 patent/WO2021141492A1/en not_active Ceased
- 2021-01-08 CN CN202180013805.8A patent/CN115066439A/zh active Pending
- 2021-01-08 EP EP21700098.3A patent/EP4087872A1/en active Pending
- 2021-01-08 JP JP2022542247A patent/JP2023509973A/ja active Pending
- 2021-01-08 IL IL294342A patent/IL294342A/en unknown
- 2021-01-08 CN CN202211674336.7A patent/CN116003604A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240317880A1 (en) | 2024-09-26 |
| CA3163286A1 (en) | 2021-07-15 |
| JP2023509973A (ja) | 2023-03-10 |
| MX2022008391A (es) | 2022-09-29 |
| IL294342A (en) | 2022-08-01 |
| CN115066439A (zh) | 2022-09-16 |
| CN116003604A (zh) | 2023-04-25 |
| AU2021206586A1 (en) | 2022-07-21 |
| WO2021141492A1 (en) | 2021-07-15 |
| EP4087872A1 (en) | 2022-11-16 |
| KR20220131527A (ko) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007163A2 (pt) | Heterociclos bicíclicos como inibidores de fgfr | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2022008184A (es) | Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer. | |
| CL2021000088A1 (es) | Anticuerpos anti-cd27 (divisional de solicitud 779-2019). | |
| MX2020013348A (es) | Anticuerpos biespecificos contra dll3-cd3. | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| MX2015007846A (es) | Anticuerpos anti-b7-h4 humana y sus usos. | |
| MX379539B (es) | Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| ECSP18062538A (es) | Conjugado de enzimas terapéuticas | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| EA201490546A1 (ru) | Замещенные аннелированные пиримидины и их применение | |
| CY1114661T1 (el) | Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια | |
| EA201890915A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| MX366978B (es) | Conjugados de anticuerpo - farmaco. | |
| MX2014003832A (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| ECSP13012776A (es) | Inmunoglobulinas de dominio variable dual | |
| CO2019009815A2 (es) | Combinaciones farmacéuticas | |
| EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
| EA202091360A1 (ru) | Гуманизированные анти-liv1 антитела для лечения рака молочной железы | |
| BR112023002301A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| CL2024001347A1 (es) | Compuestos novedosos |